John Liu, MD
Endocrinology, Diabetes & Metabolism · Shawnee Mission, KSNPI 1255781274
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.2% of the total across 422 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 32 manufacturers, the largest accounting for just 15.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $2,267 and has fallen 59.7% since, to $914 in 2025.
Across 422 payments — averaging $18.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$1K
- Abbott$702
- Novo Nordisk$696
- Corcept Therapeutics$577
- Bayer$483
- Boehringer Ingelheim$398
- plus $4K from 26 others
What the payments were for
- Food & beverage$7,64799%
- Education$611%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 59 | $1,190 |
| Abbott | 56 | $702 |
| Novo Nordisk | 39 | $696 |
| Corcept Therapeutics | 27 | $577 |
| Bayer | 26 | $483 |
| Boehringer Ingelheim | 23 | $398 |
| Amneal Pharmaceuticals LLC | 21 | $364 |
| Amgen | 20 | $358 |
| Radius Health, Inc. | 14 | $320 |
| AbbVie | 17 | $273 |
| AstraZeneca(2 entities) | 15 | $262 |
| Tandem Diabetes Care, Inc. | 11 | $234 |
| Pfizer | 13 | $210 |
| Ascensia Diabetes Care US Inc. | 11 | $207 |
| Sanofi-aventis U.S. LLC | 9 | $186 |
| Mannkind Corporation | 8 | $147 |
| Merck | 9 | $146 |
| Novartis | 7 | $131 |
| Dexcom, Inc. | 3 | $103 |
| Cequr Corporation | 2 | $101 |
| Recordati_rare_diseases_inc. | 4 | $89 |
| Amarin Pharma, Inc. | 4 | $82 |
| IBSA Pharma Inc. | 4 | $68 |
| GRT US Holding, Inc. | 3 | $67 |
| Xeris Pharmaceuticals, Inc. | 4 | $60 |
| Insulet Corporation | 3 | $59 |
| Ascendis Pharma Endocrinology Inc | 2 | $52 |
| Sequel Med Tech, LLC | 2 | $48 |
| Medtronic | 3 | $45 |
| Antares Pharma, Inc. | 1 | $21 |
| Zealand Pharma US, Inc. | 1 | $15 |
| Amryt Pharma Holdings Ltd | 1 | $14 |
How this compares
$7,707 in reported general payments places this provider in the 75th percentile of 50 endocrinology, diabetes & metabolism providers in Kansas.
See all endocrinology, diabetes & metabolism providers in Kansas →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 307 | $437,951 |
| JardianceEmpagliflozin | 202 | $246,778 |
| MounjaroTirzepatide | 80 | $153,226 |
| TrulicityDulaglutide | 59 | $114,659 |
| ProliaDenosumab | 41 | $71,191 |
| Tresiba Flextouch U-200Insulin Degludec | 43 | $68,262 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 41 | $59,456 |
| Tresiba Flextouch U-100Insulin Degludec | 72 | $53,008 |
| RybelsusSemaglutide | 43 | $52,912 |
| JanuviaSitagliptin Phosphate | 50 | $46,975 |
| FarxigaDapagliflozin Propanediol | 27 | $40,590 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 73 | $37,514 |
| TradjentaLinagliptin | 51 | $34,549 |
| Novolog FlexpenInsulin Aspart | 127 | $34,360 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 32 | $34,118 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog | $696 | $503,266387 claims |
| Boehringer IngelheimJardiance, Tradjenta | $398 | $281,327253 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $1,190 | $272,785158 claims |
| AmgenProlia | $358 | $71,19141 claims |
| MerckJanuvia | $146 | $46,97550 claims |
| AstraZenecaFarxiga | $262 | $40,59027 claims |
| Radius Health, Inc.Tymlos | $320 | $31,25212 claims |
| AbbVieSynthroid | $273 | $10,806119 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $364 | $3,724350 claims |
| Sanofi-aventis U.S. LLCLantus | $186 | $3,01626 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 50 endocrinology, diabetes & metabolism providers in Kansas.
Other endocrinology, diabetes & metabolism in Shawnee Mission
- Andrew GreenShawnee Mission$322K
- Dany ZayourWichita$744K
- Michael SokolOverland Park$227K
- Rami MortadaWichita$105K
- Sajeev MenonOverland Park$25K
- Georges ElhomsyWichita$14K
- Richard GomendozaSalina$13K
- John MilesKansas City$13K
- Nichole SmithMerriam$9K
- Susan BrianTopeka$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.